Allspring Global Investments Holdings LLC Takes $3.96 Million Position in Roivant Sciences Ltd. $ROIV

Allspring Global Investments Holdings LLC bought a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the first quarter, HoldingsChannel reports. The institutional investor bought 142,134 shares of the company’s stock, valued at approximately $3,957,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. SBI Securities Co. Ltd. boosted its position in shares of Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its holdings in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in Roivant Sciences in the fourth quarter worth approximately $47,000. CIBC Private Wealth Group LLC increased its holdings in shares of Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after buying an additional 2,665 shares in the last quarter. Finally, Clearstead Advisors LLC lifted its position in shares of Roivant Sciences by 141.6% during the 4th quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock valued at $63,000 after acquiring an additional 1,704 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ROIV. HC Wainwright reissued a “buy” rating and set a $34.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Leerink Partners set a $42.00 price target on Roivant Sciences in a research report on Thursday, May 21st. Citigroup lifted their price target on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Guggenheim upped their price objective on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Insider Activity

In related news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the transaction, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. This trade represents a 11.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 17,750 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the sale, the director owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. This trade represents a 51.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,855,913 shares of company stock valued at $62,649,633. Insiders own 10.80% of the company’s stock.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $35.01 on Friday. Roivant Sciences Ltd. has a fifty-two week low of $10.90 and a fifty-two week high of $37.00. The stock’s 50-day moving average is $32.24 and its two-hundred day moving average is $28.62. The firm has a market cap of $25.18 billion, a P/E ratio of -58.35 and a beta of 1.11.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.